AnaptysBio Newsroom

Truist Financial Maintains AnaptysBio(ANAB.US) With Hold Rating, Maintains Target Price $20

Futu NewsDec 21 02:36

J.P. Morgan Maintains AnaptysBio(ANAB.US) With Buy Rating, Cuts Target Price to $36

Futu NewsDec 21 02:36

JP Morgan Maintains Overweight on AnaptysBio, Lowers Price Target to $36

BenzingaDec 20 01:06

Truist Financial Maintains AnaptysBio(ANAB.US) With Hold Rating, Announces Target Price $20

Futu NewsDec 19 18:34

Stifel Maintains AnaptysBio(ANAB.US) With Buy Rating, Cuts Target Price to $41

Futu NewsDec 17 10:32

Stifel Nicolaus Sticks to Their Buy Rating for AnaptysBio (ANAB)

TipRanksDec 17 10:06

Analysts Offer Insights on Healthcare Companies: Keros Therapeutics (KROS), AnaptysBio (ANAB) and US Physical Therapy (USPH)

TipRanksDec 16 13:53

UBS Adjusts AnaptysBio Price Target to $18 From $33, Maintains Neutral Rating

MT NewswiresDec 13 22:51

AnaptysBio Analyst Ratings

BenzingaDec 13 18:10

AnaptysBio Is Maintained at Overweight by Wells Fargo

Dow JonesDec 13 03:26

Guggenheim Maintains AnaptysBio(ANAB.US) With Buy Rating, Announces Target Price $36

Futu NewsDec 12 21:31

Wells Fargo Maintains AnaptysBio(ANAB.US) With Buy Rating, Cuts Target Price to $40

Futu NewsDec 12 19:31

TD Cowen Maintains AnaptysBio(ANAB.US) With Buy Rating, Announces Target Price $32

Futu NewsDec 12 02:31

AnaptysBio (ANAB) Receives a Buy From TD Cowen

TipRanksDec 12 02:30

AnaptysBio Analyst Ratings

BenzingaDec 12 01:44

Hold Rating on AnaptysBio Amidst Setbacks in ANB032 and Rosnilimab Efficacy

TipRanksDec 12 01:39

HC Wainwright Downgrades AnaptysBio to Neutral From Buy, $19 Price Target

MT NewswiresDec 12 01:34

Wedbush Cuts Price Target on AnaptysBio to $40 From $42, Maintains Outperform Rating

MT NewswiresDec 11 23:05

BTIG Maintains AnaptysBio(ANAB.US) With Hold Rating

Futu NewsDec 10 18:36

Analysts Offer Insights on Healthcare Companies: AnaptysBio (ANAB), Revvity (RVTY) and McKesson (MCK)

TipRanksDec 6 14:03